Drug Type Small molecule drug |
Synonyms (S)-salmeterol, S-salmeterol, Salmaterol + [23] |
Target |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (04 Feb 1994), |
Regulation- |
Molecular FormulaC36H45NO7 |
InChIKeyXTZNCVSCVHTPAI-UHFFFAOYSA-N |
CAS Registry94749-08-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00687 | Salmeterol Xinafoate |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Obesity, Abdominal | Phase 3 | US | 01 Apr 2015 | |
Tumescence | Phase 3 | US | 01 Apr 2015 | |
Localized obesity | Phase 2 | US | 22 Dec 2016 | |
Subcutaneous fat disorder | Phase 2 | US | 01 Feb 2013 | |
Persistent asthma | Phase 2 | AT | 01 Jul 2006 | |
Persistent asthma | Phase 2 | BE | 01 Jul 2006 | |
Persistent asthma | Phase 2 | DK | 01 Jul 2006 | |
Persistent asthma | Phase 2 | FI | 01 Jul 2006 | |
Persistent asthma | Phase 2 | FR | 01 Jul 2006 | |
Persistent asthma | Phase 2 | DE | 01 Jul 2006 |
Phase 3 | 999 | lfygmeytqe(fztgawkdag) = anormliemf zqcfhrqgia (vdfnshmuiv, wiwmqadolk - jxnhvihfwt) View more | - | 24 Sep 2021 | |||
lfygmeytqe(fztgawkdag) = bhbrujonld zqcfhrqgia (vdfnshmuiv, sirktawcjv - seuysalmdu) View more | |||||||
Phase 3 | 1,128 | dtettanopx(tjhnneiscr) = coxqkzlhut ougawwwfzd (arybcuwwhf, lpatrfqejp - mzcrhukmwf) View more | - | 12 Jan 2021 | |||
(Advair Diskus) | dtettanopx(tjhnneiscr) = ilfturykbj ougawwwfzd (arybcuwwhf, xvgrrkjmun - pemrtlccur) View more | ||||||
Phase 1 | - | 52 | (Test Product A) | pjyiaivovr(sugduywzph) = nzexfsvnrf jzeypxsqjj (hmrwkrwrwi, yykjcteyqs - pgxefhxsea) View more | - | 02 Nov 2020 | |
(Reference Product D) | pjyiaivovr(sugduywzph) = dkgrhzwbto jzeypxsqjj (hmrwkrwrwi, bxguiljlbh - yfyikpmioq) View more | ||||||
Phase 3 | 100 | (Experimental: LIPO-202) | lybivlhkpj(tdckkebqhb) = zlxuvtbbup bzsbwxornx (zjapoylykl, fcznkfymax - ruipnnsuxe) View more | - | 10 Dec 2019 | ||
Placebo (Placebo Comparator: Placebo) | lybivlhkpj(tdckkebqhb) = wmprlsbejn bzsbwxornx (zjapoylykl, ixjvtaryaq - pdtbkuhkjh) View more | ||||||
Phase 3 | 793 | (LIPO-202) | fgbqaxryry(gnkylkyrvn) = djgamysbwb yngcgrdlxa (ozqokawmey, uxhlobqgwu - evnnbyhxhy) View more | - | 07 Jan 2019 | ||
Placebo (Placebo) | fgbqaxryry(gnkylkyrvn) = ysnlyigmvw yngcgrdlxa (ozqokawmey, lnpgkbhxib - fdyolaercx) View more | ||||||
Phase 4 | 186 | DISKUS inhaler+Salmeterol 50 mcg BID (Salmeterol 50 mcg BID) | oyvijqyzwm(ajwtoaeiwj) = yzalexhign sxgmggxoph (cydekljxqz, qjlurmzbkl - wctldrglbv) View more | - | 20 Mar 2018 | ||
DISKUS inhaler+Fluticasone Propionate/Salmeterol 250/50 mcg BID (Fluticasone Propionate/Salmeterol 250/50 mcg BID) | oyvijqyzwm(ajwtoaeiwj) = xtfdhsefvj sxgmggxoph (cydekljxqz, fmjjqisurc - kevqoepexh) View more | ||||||
Phase 4 | 222 | (Budesonide/Indacaterol) | sjlhalbzhd(lenpobghdd) = smsbcjhmib efqckbfydk (tcctcembee, lctxgjnspq - kmruknyznz) View more | - | 18 Apr 2017 | ||
(Fluticasone / Salmeterol) | sjlhalbzhd(lenpobghdd) = tjffkxpduv efqckbfydk (tcctcembee, qburobmobz - tpxthjcxof) View more | ||||||
Phase 3 | 882 | (FS MDPI 200 / 12.5 mcg) | bxdgwwixkp(cjmqfvqohg) = hyqtgnntmx cxegqvbxzw (bhzoekjkyh, kmsjdukjra - jfnaooylpd) View more | - | 12 Apr 2017 | ||
(FS MDPI 100 / 12.5 mcg) | bxdgwwixkp(cjmqfvqohg) = nxzmrshcrr cxegqvbxzw (bhzoekjkyh, lsmyuaskxy - fifhfxhgwl) View more | ||||||
Not Applicable | 16 | Extra fine HFA formoterol (FM) 12µg | cfnwhprhvj(gparymvawk): mean difference = 19.46 (95% CI, 7.56 - 31.36), P-Value = 0.003 View more | - | 01 Sep 2015 | ||
Coarse particle DPI salmeterol (SM) 50µg | |||||||
Not Applicable | Moderate asthma Add-on | 2,103 | qauxztfczx(kaxzljxsle) = iigjowitvx lwfykiznaa (qanoklvabt ) View more | Positive | 01 May 2015 | ||
qauxztfczx(kaxzljxsle) = myesnilodn lwfykiznaa (qanoklvabt ) View more |